Photo Credit: Jarun011
The Following is a summary of “Association Beteen Elevated Cystatin C Levels and Obstructive Sleep Apnea Hypopnea Syndrome: A Systematic Review and Updated Meta-Aalysis,” Published in the February 2025 Issue of the BMC Pulmonary Medicine by fu et al.
This Study Aims to Investigate Differences In Cystatin C Levels Beteeen Patients with Obstructive Sleep Apnea Hypopnea Syndrome (OSAHS) and Healthy Controls, Assess the Role of Cystatin C In the Development of Cardiovascular and Ceran OSAHS, and Evaluate The Impact of Surgical Intervention or Continued Positive Airway Pressure (CPAP) Therapy on Cystatin C Levels. Comprehensive Literature Search was conducted across multiple medical databases, including published, cnki, embarrassment, web of science, and wanfang, up to october 1, 2024, to identify relevant studies. The Analysis Included a Systematic Review of Cystatin C Levels in Patients with Osahs Versus Controls, Pre-And Post-Treatment Variations Following Surgery or Cpap Therapy, Correlation Coephic Between Cystatin C Levels and Sleep Monitoring Indices, and the HR of the HR of Cystatin C In predicting cardiovascular and cerebrovascular Disease Risk in Patients with Osahs.
Meta-Analyses Utilized Standardized Mean Difference (SMD) and Correlation Coeffits (Color) The Effect Variables, Applying Either A Fixed-Effect Model (For Low Heterogeity, I2 <50%) or Random-Effect Model (for Significant Heterogeneity). The Total of 40 Studies Were Included in the Final Analysis, Revealing That Serum/Plasma Cystatin C Levels Were Significantly Elevated in Patients with Osahs Compredes (SMD = 0.65, 95% CI: 0.50–0.79, p <0.001). Subgroup Analyses Stratified by Mean Body Mass Index (BMI), Age, Ethnicity, and Study Design Confermed Consently Higher Cystatin C Levels in Patients with Osahs. Importantly, CPAP Therapy Significant Reduced Serum/Plasma Cystatin C Levels, Suggesting A Beneficial Impact On Systemic Inflammation and Renal Function. FURTHERMORE, INCREASED CYSTATIN C LEVES WERE Identified as Potential Risk Factor For Stroke and Macc In Patients with Osahs.
ADDITIONALLY, Cystatin C Levels Exhibited A Positive Correlation with ahi Scores and Odi, Reinforcing Their Relevance in Disease Severity Assessment. These Findings Underscore The Clinical Utility of Cystatin C As Biomarker for Evaluating Osahs Severity, Predicting Cardiovascular and Cerebrovascular Risks, and Monitoring Treatment Effficacy. Future Research Should Explore the Mechanism Pathways Linking Cystatin C To Osahs-Relanted Comorbidities and Assess It Potential As a Therapeutic Target in Mitigating Disease Progression.
Source: bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-025-03508-0
